JP2023524794A5 - - Google Patents
Info
- Publication number
- JP2023524794A5 JP2023524794A5 JP2022567451A JP2022567451A JP2023524794A5 JP 2023524794 A5 JP2023524794 A5 JP 2023524794A5 JP 2022567451 A JP2022567451 A JP 2022567451A JP 2022567451 A JP2022567451 A JP 2022567451A JP 2023524794 A5 JP2023524794 A5 JP 2023524794A5
- Authority
- JP
- Japan
- Prior art keywords
- abiraterone acetate
- pharmaceutical preparation
- niraparib
- patient
- prednisone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20173749 | 2020-05-08 | ||
| EP20173749.1 | 2020-05-08 | ||
| US202163142919P | 2021-01-28 | 2021-01-28 | |
| US63/142,919 | 2021-01-28 | ||
| US202163174282P | 2021-04-13 | 2021-04-13 | |
| US63/174,282 | 2021-04-13 | ||
| PCT/EP2021/062180 WO2021224467A1 (en) | 2020-05-08 | 2021-05-07 | Treatment of prostate cancer with a combination of abiraterone acetate and niraparib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524794A JP2023524794A (ja) | 2023-06-13 |
| JP2023524794A5 true JP2023524794A5 (https=) | 2024-05-10 |
Family
ID=75888052
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567542A Pending JP2023524808A (ja) | 2020-05-08 | 2021-05-07 | アビラテロン酢酸エステル及びニラパリブの組み合わせでの前立腺癌の治療 |
| JP2022567447A Pending JP2023525026A (ja) | 2020-05-08 | 2021-05-07 | 酢酸アビラテロン及びニラパリブの医薬製剤 |
| JP2022567451A Pending JP2023524794A (ja) | 2020-05-08 | 2021-05-07 | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567542A Pending JP2023524808A (ja) | 2020-05-08 | 2021-05-07 | アビラテロン酢酸エステル及びニラパリブの組み合わせでの前立腺癌の治療 |
| JP2022567447A Pending JP2023525026A (ja) | 2020-05-08 | 2021-05-07 | 酢酸アビラテロン及びニラパリブの医薬製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20230226080A1 (https=) |
| EP (3) | EP4146210A1 (https=) |
| JP (3) | JP2023524808A (https=) |
| KR (3) | KR20230008780A (https=) |
| CN (3) | CN115515584A (https=) |
| AU (5) | AU2021267146B2 (https=) |
| BR (3) | BR112022021732A2 (https=) |
| CA (3) | CA3177123A1 (https=) |
| CR (1) | CR20220588A (https=) |
| EC (1) | ECSP22085983A (https=) |
| IL (3) | IL297984B2 (https=) |
| JO (3) | JOP20220294A1 (https=) |
| MX (3) | MX2022014003A (https=) |
| PE (1) | PE20230830A1 (https=) |
| PH (3) | PH12022553029A1 (https=) |
| TW (3) | TWI905184B (https=) |
| UA (1) | UA130040C2 (https=) |
| UY (3) | UY39204A (https=) |
| WO (3) | WO2021224467A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243120A1 (en) * | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and changes in hormone receptor function (HRF) |
| WO2025027138A1 (en) * | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2132449C (en) | 1992-03-31 | 2002-09-10 | Susan E. Barrie | 17 - substituted steroids useful in cancer treatment |
| JP2003104888A (ja) * | 2001-09-28 | 2003-04-09 | Taiyo Yakuhin Kogyo Kk | ジヒドロピリジン誘導体の錠剤 |
| BRPI0719236A2 (pt) * | 2006-10-13 | 2014-07-08 | Janssen Pharmaceutica Nv | Composições de carbamato de fenilalquila |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| CN102026628A (zh) * | 2008-02-15 | 2011-04-20 | 太阳医药高级研发有限公司 | 具有降低崩裂效果的口服控释片剂 |
| CA2808501A1 (en) * | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| CN102743393A (zh) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
| HK1213197A1 (zh) * | 2013-03-04 | 2016-06-30 | Vtv治疗有限责任公司 | 包括葡糖激酶活化劑的固體組合物及其製備和使用方法 |
| WO2015032873A1 (en) * | 2013-09-06 | 2015-03-12 | Synthon B.V. | High-load pharmaceutical compositions comprising abiraterone acetate |
| EP3160450A1 (en) * | 2014-06-30 | 2017-05-03 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate release tablets |
| SG11201701139YA (en) * | 2014-09-18 | 2017-03-30 | Iceutica Inc | Abiraterone acetate formulation and methods of use |
| SG11201811564QA (en) * | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN110944638A (zh) * | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| HUE060460T2 (hu) * | 2017-04-13 | 2023-03-28 | Janssen Pharmaceutica Nv | Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére |
| TWI843707B (zh) * | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| JOP20200072A1 (ar) * | 2017-10-11 | 2020-04-29 | Janssen Oncology Inc | طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين |
| CA3098208A1 (en) * | 2018-04-26 | 2019-10-31 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| CN113166071B (zh) | 2018-10-03 | 2025-03-21 | 特沙诺有限公司 | 尼拉帕利盐 |
-
2021
- 2021-05-07 TW TW110116507A patent/TWI905184B/zh active
- 2021-05-07 KR KR1020227042483A patent/KR20230008780A/ko active Pending
- 2021-05-07 UY UY0001039204A patent/UY39204A/es unknown
- 2021-05-07 BR BR112022021732A patent/BR112022021732A2/pt unknown
- 2021-05-07 TW TW110116509A patent/TWI894266B/zh active
- 2021-05-07 IL IL297984A patent/IL297984B2/en unknown
- 2021-05-07 PH PH1/2022/553029A patent/PH12022553029A1/en unknown
- 2021-05-07 MX MX2022014003A patent/MX2022014003A/es unknown
- 2021-05-07 JP JP2022567542A patent/JP2023524808A/ja active Pending
- 2021-05-07 WO PCT/EP2021/062180 patent/WO2021224467A1/en not_active Ceased
- 2021-05-07 WO PCT/EP2021/062186 patent/WO2021224469A1/en not_active Ceased
- 2021-05-07 US US17/998,202 patent/US20230226080A1/en active Pending
- 2021-05-07 EP EP21725098.4A patent/EP4146210A1/en active Pending
- 2021-05-07 AU AU2021267146A patent/AU2021267146B2/en active Active
- 2021-05-07 BR BR112022022590A patent/BR112022022590A2/pt active IP Right Grant
- 2021-05-07 CN CN202180033488.6A patent/CN115515584A/zh active Pending
- 2021-05-07 UY UY0001039201A patent/UY39201A/es unknown
- 2021-05-07 IL IL297991A patent/IL297991A/en unknown
- 2021-05-07 US US17/998,198 patent/US20230218640A1/en active Pending
- 2021-05-07 CA CA3177123A patent/CA3177123A1/en active Pending
- 2021-05-07 AU AU2021269115A patent/AU2021269115A1/en active Pending
- 2021-05-07 CA CA3177137A patent/CA3177137A1/en active Pending
- 2021-05-07 CN CN202180033482.9A patent/CN115515583A/zh active Pending
- 2021-05-07 JP JP2022567447A patent/JP2023525026A/ja active Pending
- 2021-05-07 UY UY0001039203A patent/UY39203A/es unknown
- 2021-05-07 JP JP2022567451A patent/JP2023524794A/ja active Pending
- 2021-05-07 PH PH1/2022/553013A patent/PH12022553013A1/en unknown
- 2021-05-07 EP EP21725101.6A patent/EP4146211A1/en active Pending
- 2021-05-07 UA UAA202204571A patent/UA130040C2/uk unknown
- 2021-05-07 EP EP21724665.1A patent/EP4146209A1/en active Pending
- 2021-05-07 PE PE2022002554A patent/PE20230830A1/es unknown
- 2021-05-07 MX MX2022014005A patent/MX2022014005A/es unknown
- 2021-05-07 IL IL297990A patent/IL297990A/en unknown
- 2021-05-07 PH PH1/2022/553030A patent/PH12022553030A1/en unknown
- 2021-05-07 CN CN202180033483.3A patent/CN115551506A/zh active Pending
- 2021-05-07 KR KR1020227042489A patent/KR20230008782A/ko active Pending
- 2021-05-07 MX MX2022014004A patent/MX2022014004A/es unknown
- 2021-05-07 CA CA3177094A patent/CA3177094A1/en active Pending
- 2021-05-07 WO PCT/EP2021/062188 patent/WO2021224471A1/en not_active Ceased
- 2021-05-07 BR BR112022022534A patent/BR112022022534A2/pt active IP Right Grant
- 2021-05-07 TW TW110116506A patent/TW202207925A/zh unknown
- 2021-05-07 AU AU2021266409A patent/AU2021266409A1/en active Pending
- 2021-05-07 KR KR1020227042495A patent/KR20230008783A/ko active Pending
- 2021-05-07 US US17/998,204 patent/US20230226081A1/en active Pending
- 2021-05-07 CR CR20220588A patent/CR20220588A/es unknown
-
2022
- 2022-11-01 JO JOJO/P/2022/0294A patent/JOP20220294A1/ar unknown
- 2022-11-01 JO JOJO/P/2022/0288A patent/JOP20220288A1/ar unknown
- 2022-11-01 JO JOJO/P/2022/0292A patent/JOP20220292A1/ar unknown
- 2022-11-08 EC ECSENADI202285983A patent/ECSP22085983A/es unknown
-
2025
- 2025-12-11 US US19/415,909 patent/US20260097048A1/en active Pending
-
2026
- 2026-03-23 AU AU2026202227A patent/AU2026202227A1/en active Pending
- 2026-03-25 AU AU2026202283A patent/AU2026202283A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hack et al. | Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities | |
| JP7198310B2 (ja) | 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤 | |
| Haas et al. | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies | |
| JP6833816B2 (ja) | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） | |
| KR20150103284A (ko) | 변경된 공간 배열을 갖는 재조합 인터페론을 사용함에 의해 종양을 치료하기 위한 방법 | |
| JP2023524794A5 (https=) | ||
| US20250090514A1 (en) | Method of treating cancer | |
| Rallis et al. | Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances | |
| JP2023524808A5 (https=) | ||
| JP2023525026A5 (https=) | ||
| JP2023531683A5 (https=) | ||
| KR20260033049A (ko) | 전립선암 치료 방법 | |
| JP2023524808A (ja) | アビラテロン酢酸エステル及びニラパリブの組み合わせでの前立腺癌の治療 | |
| KR20250154416A (ko) | 신경교종을 치료하는데 사용하기 위한 테모졸로마이드 및 방사선요법과 병용한 debio-0123 | |
| US12280049B2 (en) | Methods of delaying pain progression and treating prostate cancer | |
| Comito et al. | Systemic and liver-directed therapies in metastatic uveal melanoma: State-of-the-art and novel perspectives | |
| Whitehead et al. | A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study | |
| TWI547286B (zh) | 趨化激素受體拮抗劑及其組合療法 | |
| US20250170146A1 (en) | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations | |
| HK40116103A (zh) | 尼拉帕尼和醋酸阿比特龙加泼尼松用於改善患有转移性去势抵抗性前列腺癌和hrr改变的患者的临床结果 | |
| Deng¹ et al. | and GM-CSF in oligometastatic | |
| Salam | Metastatic Hormone Sensitive Prostate Cancer, New Management Protocol, 2023 | |
| Miras Rodriguez et al. | COBIMETINIB FOR TREATING PATIENTS WITH BRAF WILD-TYPE ERDHEIM-CHESTER DISEASE | |
| Lit et al. | complicating TP53 mutation treated successfully with | |
| Wei et al. | Glioblastoma insights: Focus on crosstalk with the suppressive tumor microenvironment and advanced therapeutic strategies |